Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 16, 2024 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
May 16, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first...
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 15, 2024 16:15 ET
|
Fortress Biotech, Inc.
Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA...
JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé Farmaceutici S.p.A, Sanofi, Celgene, AstraZeneca, Karyopharm Therapeutics
May 15, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 15, 2024 (GLOBE NEWSWIRE) -- JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé...
Oligonucleotide Synthesis Market is Expected to Reach $19.7 billion | MarketsandMarkets™
May 15, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 15, 2024 (GLOBE NEWSWIRE) -- Oligonucleotide Synthesis market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at...
Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain
May 14, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 14, 2024 (GLOBE NEWSWIRE) -- Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain ...
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
May 14, 2024 08:30 ET
|
Fortress Biotech, Inc.
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical trial...
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee
May 14, 2024 03:00 ET
|
Nouscom Srl
Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that...
Uterine Sarcoma Treatment Market To Reach USD 5.9 Billion By 2032 | DataHorizzon Research
May 14, 2024 01:52 ET
|
DataHorizzon Research
Fort Collins, Colorado, May 14, 2024 (GLOBE NEWSWIRE) -- Rising incidences of uterine sarcoma in the population drive the need for treatment. The growth of the uterine sarcoma treatment market is...
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
May 13, 2024 16:01 ET
|
Voyager Therapeutics, Inc.
- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks - -...